NeuroXess Completes RMB 700 Million Series B Financing, Co-Led by SDIC Unity Capital, SCGC, and Triwise Capital

[Shanghai, October 28, 2026] NeuroXess announced today the completion of its RMB 700 million Series B financing round. This round was jointly led by SDIC Unity Capital, Shenzhen Capital Group (SCGC), and Triwise Capital, with participation from renowned institutional co-investors including China Fortune-Tech Capital, Huangpu Investment,Cornerstone Capital, IDG Capital, Xichen Capital, Junxi Capital, Huafu Securities, Huasai Zhihui, ZWC Partners, and Jiangxi Financial Holding. Existing investors including Shanda Group and Zhongping Capital continued their steadfast support. The proceeds will be allocated toward multi-center registered clinical trials and regulatory approvals for the Fully-implanted, Fully-wireless, and Fully-functional (“Triple-F”) brain-computer interface (BCI) system, the construction and ramp-up of the Giga-factory, as well as next-generation product R&D and the exploration of BCI+AI convergence.

Since its launch, this financing round has garnered substantial attention across the capital markets, drawing an investor base encompassing state-owned capital platforms, semiconductor industrial funds, healthcare-focused venture capital, and deep-tech investment institutions, thereby establishing a multi-tiered, cross-sector investment syndicate. This momentum reflects the BCI industry’s transition from proof-of-concept validation to scaled commercial implementation. Leveraging full-stack proprietary R&D capabilities, a well-defined registered clinical pathway, and robust industrialization progress,NeuroXess has solidified its position as a highly sought-after core asset in the field.

Three Anchor Institutions Jointly Lead the Round, Harnessing Synergies Across Multi-Tiered Capital

The strategic participation of state-owned capital systems represents the most salient feature of this financing round. As an investment affiliate of State Development and Investment Corp. (SDIC), SDIC Unity Capital’s participation reflects central state-owned enterprise funds’ strong conviction and confidence in the emerging industrialization window for BCIs.As one of China’s premier state-backed venture capital institutions, SCGC has taken a bullish, high-conviction position in the BCI sector, designating NeuroXess as its strategic flagship investment.

Representing healthcare innovation among the co-lead investors, Triwise Capital infuses deep medical industry resources into NeuroXess. With an extensive track record in biopharmaceuticals and high-end medical devices, Triwise Capital’s co-lead investment not only acknowledges NeuroXess’s foundational deep-tech capabilities, but will also accelerate the clinical and commercial translation of the “Triple-F” BCI system across serious medical indications. As an essential strategic participant in this round, Huangpu Investment has consistently tracked and fostered the company’s growth since NeuroXess established its presence in Huangpu District in 2021.

The joint participation of Huangpu Investment and Jiangxi Financial Holding serves as a vivid manifestation of the “Shanghai-Jiangxi Collaboration” on the capital front—tying Shanghai’s innovative R&D origins to Jiangxi’s manufacturing scale through capital syndication.

“The industrialization window for brain-computer interfaces is rapidly opening, yet few companies have successfully closed the loop from clinical trials to scaled commercial delivery. NeuroXess has achieved full-stack proprietary R&D spanning both hardware and software, and its ‘Triple-F’ system has established a clinically reproducible surgical paradigm,representing the Chinese solution closest to complete industrialization that we have observed globally. SDIC Unity Capital chose NeuroXess not only for its authority in defining sector standards, but also for its pioneering exploration into BCI+AI convergence, which perfectly aligns with our overarching thesis on AI industrial trends. Leveraging business synergies and regional resources within the SDIC Group ecosystem, we will fully empower NeuroXess in achieving scaled industrial deployment.”

— SDIC Unity Capital

“Brain-computer interface technology stands as one of the six frontier future industries strategically prioritized in China’s 15th Five-Year Plan, serving as a vital engine for cultivating new quality productive forces. NeuroXess possesses formidable capabilities in engineering execution and clinical translation, having completed clinical validation across multiple participants and advancing toward exploring real-world physical models via BCI. Relying on SCGC’s platform resources, we will empower NeuroXess to accelerate its corporate trajectory, and we look forward to the company continuing to deepen its clinical exploration, advance steadily toward scaled industrialization, and provide valuable benchmarks for innovative practices in China’s BCI arena.”

— Shenzhen Capital Group (SCGC)

“Brain-computer interfaces represent the ultimate frontier where neuroscience converges with artificial intelligence.NeuroXess is among the exceptionally rare Chinese enterprises globally that have executed a complete, end-to-end clinical closed loop. Triwise Capital co-led this round not only out of recognition for its foundational deep-tech capabilities, but also because of our confidence in its broad potential to emerge from serious medical applications into the definitive interface for next-generation human-machine interaction. Leveraging our healthcare industrial ecosystem, we will fully support NeuroXess in accelerating multi-center clinical trials and product regulatory clearances.”

— Triwise Capital

“NeuroXess serves as the anchor enterprise within Huangpu District’s BCI industrial cluster. Huangpu has introduced the ’10 Measures for BCI Services,’ providing full-spectrum lifecycle support spanning core R&D breakthroughs, medical device registration, and pilot demonstration scenarios. Huangpu Investment will continue to harness its platform capabilities to facilitate NeuroXess’s integration into an innovation ecosystem uniting industrial chains, innovation pipelines, and professional services.”

— Wang Yiping, Chairman of Huangpu Investment

Cross-Sector Capital Positions Aggressively: Top-Tier Investors Secure Strategic Stakes in Next-Generation Interaction Interfaces

Beyond the strategic backing of national and municipal state-owned funds, another prominent facet of this round is the concentrated entry of leading cross-sector capital. China Fortune-Tech Capital (a premier corporate VC deeply embedded in the semiconductor supply chain), Cornerstone Capital (a prominent private equity firm with a sustained focus on full-lifecycle deep tech), and top-tier global venture firm IDG Capital jointly form a diversified, institutional investment matrix. Furthermore, follow-on investments from established shareholders such as Shanda Group and Zhongping Capital reinforce the market’s long-term conviction in NeuroXess.

This collective commitment from leading institutions across semiconductors, premier venture capital, and healthtech signals that BCI is evolving from a vertical clinical niche into a foundational cross-industry infrastructure. This interdisciplinary alliance not only affirms NeuroXess’s full-stack proprietary technical prowess and clinical milestones,but also reflects a shared market consensus and preemptive positioning around BCI as the definitive portal for next-generation human-machine symbiosis.

Accelerating Industrialization: Targeting Scaled Medical Market Commercialization Within Two Years

On the industrialization front, NeuroXess has commenced construction of its “Giga-factory,” covering a planned area of 14,300 square meters with the target of achieving annual delivery capacity in the tens of thousands of units. On the clinical validation front, NeuroXess has completed 65 clinical trials. On July 7, 2026, the “Triple-F” BCI system officially commenced its GCP registered clinical trial at Huashan Hospital Affiliated to Fudan University, led by Professor Ying Mao’s team as Principal Investigator in collaboration with nearly 20 Grade-A tertiary hospitals nationwide. This represents China’s first subdural semi-invasive BCI system to enter the registered clinical phase for Class III medical devices.

Proceeds from this financing round will be channeled into four key directions: multi-center registered clinical trials and regulatory clearances for the “Triple-F” system, Giga-factory mass production infrastructure, next-generation product development, and the ongoing exploration of BCI-AI convergence. Next-generation product development will focus on the continuous iteration and optimization of speech BCIs while accelerating visual BCI research pipelines to expand clinical indications. Concurrently, BCI-AI integration initiatives will concentrate on intent-driven AI interaction, external tool control, and ambient environment orchestration to explore BCI+AI real-world physical models, capturing neural dynamics across real-life scenarios to unlock the broader potential of next-generation human-machine interfaces.NeuroXess aims to achieve scaled commercial translation in the medical market within two years, delivering tangible benefits of frontier technology to a broader patient population.

Dr. Tiger H. Tao, Founder, CEO, and Chief Scientist of NeuroXess, stated: “We are deeply grateful for the trust of our investors. This round will accelerate NeuroXess’s transition from clinical validation to scaled commercial implementation.We remain committed to safer methodologies that achieve superior clinical efficacy, enabling patients to reclaim their lives with dignity and quality. Moving forward, we will coordinate industrial supply chains and expand our collaborative ecosystem, establishing BCI as the bridge between the human brain and the physical world while exploring BCI+AI real-world physical models. The BCI landscape is vast and thrives on diverse innovation. We look forward to joining hands with industry peers to advance Chinese solutions, define industry standards, and elevate patient well-being.”